MARINUS PHARMACEUTICALS INC (MRNS) Stock News

USA - NASDAQ:MRNS - US56854Q2003 - Common Stock

0.55 USD

+0 (+0.09%)

Last: 2/10/2025, 8:13:23 PM

0.5491 USD

0 (-0.16%)

Pre-Market: 2/11/2025, 5:16:41 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MRNS Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Bragar Eagel & Squire

MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

8 months ago - By: Halper Sadeh LLC - Mentions: OMIC VCSA

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates OMIC, MRNS, VCSA on Behalf of Shareholders

a year ago - By: BusinessInsider

News Image

MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024

8 months ago - By: Kahn Swick & Foti, LLC

MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS

8 months ago - By: Brodsky & Smith LLC - Mentions: ML NYSE NEUE GEN

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MoneyLion Inc. (NYSE - ML), Marinus Pharmaceuticals, Inc. (Nasdaq - MRNS), Better Choice Inc. (NYSE American - BTTR), NeueHealth, Inc. (NYSE - NEUE)

9 months ago - By: Halper Sadeh LLC - Mentions: VCSA MHLD

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders

9 months ago - By: Benzinga - Mentions: CVM CPHI ABP SENS ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

9 months ago - By: Benzinga

Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%

9 months ago - By: Ademi LLP

Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders

9 months ago - By: Halper Sadeh LLC

MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders

9 months ago - By: Marinus Pharmaceuticals

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

10 months ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

a year ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

a year ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

a year ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens

a year ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

a year ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

a year ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

a year ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024

a year ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

a year ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024

a year ago - By: InvestorPlace

MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024

a year ago - By: Marinus Pharmaceuticals

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

a year ago - By: InvestorPlace - Mentions: LYEL OCUL

3 Biotech Stocks to Sell in August Before They Crash & Burn

a year ago - By: The Schall Law Firm

MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

a year ago - By: The Gross Law Firm

Marinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS

a year ago - By: THE ROSEN LAW FIRM, P. A.

MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by Rosen Law Firm